Publications

Found 3 results

Sort by: Author [ Title  (Asc)] Type Year
Filters: First Letter Of Title is A  [Clear All Filters]
[A] B C D E F G H I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
A
KHALFAN DRABDALLAHFATMAH. "Abdallah F K , Mwanda W O, .". In: Africa Sanguine . 2006 ; 9;1;1 1-6. The East and Central African Journal of Pharmaceutical Sciences.; 2006. Abstract

OBJECTIVE: To document the impact of fixed dose weight adjusted filgastrim (G-CSF) in cytotoxic-induced neutropaenia. DESIGN: A descriptive cross-sectional study. SETTING: Paediatric Oncology Unit at Kenyatta National Hospital, Nairobi, Kenya. SUBJECTS: All paediatric oncology patients who had developed cytotoxic-induced neutropaenia. MAIN OUTCOME MEASURES: The following were documented for every tissue proven case of malignancy; age, sex, type of malignancy, treatment regimen and schedule, initial blood count at the time of neutropaenia; subsequent blood counts daily for five days from day one of single dose filgastrim, and the calculated neutrophil incremental count. RESULTS: Initially eight patients with solid tumours previously treated with filgastrim revealed that cytotoxic induced neutropaenia could be ameliorated by a single dose of filgastrim. Subsequently, the study listed thirty patients. This cohort consisted of; 37% rhabdomyosarcoma, 30% Burkitts, 27% acute lymphoblastic leukaemia and 6% Hodgkin's lymphoma. Increased neutrophil count after 48 hours was documented in 26 (87%) patients, with absolute neutrophil counts range of 0.5 to 31.5 x 10(9)/L. This response was significantly influenced by gender (p>0.0001), malignancy type and chemotherapy regimen (p>0.001). CONCLUSION: The study shows that chemotherapy induced neutropaenia can be alleviated by a single dose of filgastrim without adverse effects on lymphoblastic leukaemia. This study suggests that a single dose of filgastrim should be first tried in cytotoxic induced neutropaenia in the paediatric age group.

KHALFAN DRABDALLAHFATMAH. "Abdallah FA .". In: EAMJ , Jan 2008 ; 85 ; 16-21. The East and Central African Journal of Pharmaceutical Sciences.; 2008. Abstract
Normal 0 false false false EN-GB X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin-top:0cm; mso-para-margin-right:0cm; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0cm; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"Times New Roman"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;} Clematis brachiata Thunberg (Ranunculaceae) is used in Kenya for the management of headaches, malaria and other febrile illnesses, abdominal disorders, yaws and for skin disorders.  Old stems and leaves are chewed for the management of toothaches and sore throats.  Extracts of the plant were subjected to tests for antimalarial, antibacterial and antifungal activity.  The toxicity of the extracts was assessed using the brine shrimp lethality bioassay.   The root extract gave the highest in vitro antimalarial activity against a mulitidrug resistant strain, Plasmodium falciparum VI/S (IC50=39.24 mg/ml). The stem and leaf extracts had insignificant antiplasmodial activity.  The leaf, stem and root extracts had bacterial or fungal growth even at very high concentrations of 10 mg/ml. The LD50 values of the stem and leaf methanol extracts against the brine shrimp larvae was 365.60 and 66.5 mg/ml respectively. The in vitro anti malarial activity of the root extract in part supports the ethnobotanical use of the plant to manage malaria.  KEY WORDS Clematis, Ranunculaceae, antimalarial, brine shrimp, antimicrobial
KHALFAN DRABDALLAHFATMAH. "Abdallah FK. Single dose filgastrim in cytotoxic-induced neutropaenia in children. East Afr Med J. 2008 Jan;85(1):30-5.". In: ast Afr Med J. 2008 Jan;85(1):30-5. The East and Central African Journal of Pharmaceutical Sciences.; 2008. Abstract

OBJECTIVE: To document the impact of fixed dose weight adjusted filgastrim (G-CSF) in cytotoxic-induced neutropaenia. DESIGN: A descriptive cross-sectional study. SETTING: Paediatric Oncology Unit at Kenyatta National Hospital, Nairobi, Kenya. SUBJECTS: All paediatric oncology patients who had developed cytotoxic-induced neutropaenia. MAIN OUTCOME MEASURES: The following were documented for every tissue proven case of malignancy; age, sex, type of malignancy, treatment regimen and schedule, initial blood count at the time of neutropaenia; subsequent blood counts daily for five days from day one of single dose filgastrim, and the calculated neutrophil incremental count. RESULTS: Initially eight patients with solid tumours previously treated with filgastrim revealed that cytotoxic induced neutropaenia could be ameliorated by a single dose of filgastrim. Subsequently, the study listed thirty patients. This cohort consisted of; 37% rhabdomyosarcoma, 30% Burkitts, 27% acute lymphoblastic leukaemia and 6% Hodgkin's lymphoma. Increased neutrophil count after 48 hours was documented in 26 (87%) patients, with absolute neutrophil counts range of 0.5 to 31.5 x 10(9)/L. This response was significantly influenced by gender (p>0.0001), malignancy type and chemotherapy regimen (p>0.001). CONCLUSION: The study shows that chemotherapy induced neutropaenia can be alleviated by a single dose of filgastrim without adverse effects on lymphoblastic leukaemia. This study suggests that a single dose of filgastrim should be first tried in cytotoxic induced neutropaenia in the paediatric age group.

UoN Websites Search